Drug profile · INN
acrivastine
SEMPREX-D
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
acrivastine (SEMPREX-D) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN acrivastine
Brand SEMPREX-D
Route ORAL
Formulation CAPSULE
Frequently asked questions
What is acrivastine?
acrivastine (SEMPREX-D) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for acrivastine?
SEMPREX-D is a marketed brand name for acrivastine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of acrivastine?
acrivastine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.